Comparison of the clinical and cost effectiveness of two management strategies (rehabilitation versus surgical reconstruction) for non-acute anterior cruciate ligament (ACL) injury: study protocol for the ACL SNNAP randomised controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
14 May 2020
Historique:
received: 09 02 2020
accepted: 30 03 2020
entrez: 16 5 2020
pubmed: 16 5 2020
medline: 26 1 2021
Statut: epublish

Résumé

Anterior cruciate ligament (ACL) rupture is a common knee injury that can lead to poor quality of life, decreased activity and increased risk of secondary osteoarthritis of the knee. Management of patients with a non-acute ACL injury can include a non-surgical (rehabilitation) or surgical (reconstruction) approach. However, insufficient evidence to guide treatment selection has led to high variation in treatment choice for patients with non-acute presentation of ACL injury. The objective of the ACL SNNAP trial is to determine in patients with non-acute anterior cruciate ligament deficiency (ACLD) whether a strategy of non-surgical management (rehabilitation) (with option for later ACL reconstruction only if required) is more clinically effective and cost effective than a strategy of surgical management (reconstruction) without prior rehabilitation with all patients followed up at 18 months. The study is a pragmatic, multi-centre, superiority, randomised controlled trial with two-arm parallel groups and 1:1 allocation. Patients with a symptomatic non-acute ACL deficient knee will be randomised to either non-surgical management (rehabilitation) or surgical management (reconstruction). We aim to recruit 320 patients from approximately 30 secondary care orthopaedic units from across the United Kingdom. Randomisation will occur using a web-based randomisation system. Blinding of patients and clinicians to treatment allocation will not be possible because of the nature of the interventions. Participants will be followed up via self-reported questionnaires at 6, 12 and 18 months. The primary outcome is the Knee injury and Osteoarthritis Outcome Score (KOOS) at 18 months post randomisation. Secondary outcomes will include a return to sport/activity, intervention-related complications, patient satisfaction, expectations of activity, generic health quality of life, knee specific quality of life and resource usage. At present, no evidence-based treatment of non-acute ACL deficiency exists, particularly in the NHS. Moreover, little consensus exists on the management approach for these patients. The proposed trial will address this gap in knowledge regarding the clinical and cost effectiveness of ACL treatment and inform future standards of care for this condition. ISRCTN: 10110685. Registered on 16 November 2016. ClinicalTrials.gov: NCT02980367. Registered in December 2016.

Sections du résumé

BACKGROUND BACKGROUND
Anterior cruciate ligament (ACL) rupture is a common knee injury that can lead to poor quality of life, decreased activity and increased risk of secondary osteoarthritis of the knee. Management of patients with a non-acute ACL injury can include a non-surgical (rehabilitation) or surgical (reconstruction) approach. However, insufficient evidence to guide treatment selection has led to high variation in treatment choice for patients with non-acute presentation of ACL injury. The objective of the ACL SNNAP trial is to determine in patients with non-acute anterior cruciate ligament deficiency (ACLD) whether a strategy of non-surgical management (rehabilitation) (with option for later ACL reconstruction only if required) is more clinically effective and cost effective than a strategy of surgical management (reconstruction) without prior rehabilitation with all patients followed up at 18 months.
METHODS METHODS
The study is a pragmatic, multi-centre, superiority, randomised controlled trial with two-arm parallel groups and 1:1 allocation. Patients with a symptomatic non-acute ACL deficient knee will be randomised to either non-surgical management (rehabilitation) or surgical management (reconstruction). We aim to recruit 320 patients from approximately 30 secondary care orthopaedic units from across the United Kingdom. Randomisation will occur using a web-based randomisation system. Blinding of patients and clinicians to treatment allocation will not be possible because of the nature of the interventions. Participants will be followed up via self-reported questionnaires at 6, 12 and 18 months. The primary outcome is the Knee injury and Osteoarthritis Outcome Score (KOOS) at 18 months post randomisation. Secondary outcomes will include a return to sport/activity, intervention-related complications, patient satisfaction, expectations of activity, generic health quality of life, knee specific quality of life and resource usage.
DISCUSSION CONCLUSIONS
At present, no evidence-based treatment of non-acute ACL deficiency exists, particularly in the NHS. Moreover, little consensus exists on the management approach for these patients. The proposed trial will address this gap in knowledge regarding the clinical and cost effectiveness of ACL treatment and inform future standards of care for this condition.
TRIAL REGISTRATION BACKGROUND
ISRCTN: 10110685. Registered on 16 November 2016. ClinicalTrials.gov: NCT02980367. Registered in December 2016.

Identifiants

pubmed: 32410697
doi: 10.1186/s13063-020-04298-y
pii: 10.1186/s13063-020-04298-y
pmc: PMC7222454
doi:

Banques de données

ClinicalTrials.gov
['NCT02980367']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

405

Subventions

Organisme : Health Technology Assessment Programme
ID : 14/140/63

Références

Am J Sports Med. 2016 Mar;44(3):618-24
pubmed: 26792706
Am J Sports Med. 2009 May;37(5):955-61
pubmed: 19251674
Health Technol Assess. 2019 Oct;23(60):1-88
pubmed: 31661431
J Knee Surg. 2016 Jan;29(1):74-9
pubmed: 25438034
Br J Sports Med. 2004 Oct;38(5):542-4
pubmed: 15388535
Bol Asoc Med P R. 2006 Jan-Mar;98(1):62-72
pubmed: 19610551
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Orthop Sports Phys Ther. 1998 Aug;28(2):88-96
pubmed: 9699158
Arthritis Res Ther. 2014 Jul 31;16(4):R162
pubmed: 25082600
Am J Sports Med. 2012 Nov;40(11):2509-16
pubmed: 22962290
Am J Sports Med. 2009 Jul;37(7):1434-43
pubmed: 19567666
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Cochrane Database Syst Rev. 2016 Apr 03;4:CD011166
pubmed: 27039329
Am J Sports Med. 2010 Oct;38(10):2040-50
pubmed: 20709944
Injury. 1996 Jul;27(6):407-9
pubmed: 8881137
Knee. 2012 Jan;19(1):14-9
pubmed: 21216599
Knee. 2001 Mar;8(1):13-8
pubmed: 11248563
N Engl J Med. 2010 Jul 22;363(4):331-42
pubmed: 20660401
Int J Sports Phys Ther. 2014 Apr;9(2):268-73
pubmed: 24790787
Am J Sports Med. 1998 May-Jun;26(3):350-9
pubmed: 9617395
Trials. 2012 Jan 04;13:2
pubmed: 22217216
BMC Musculoskelet Disord. 2009 Aug 10;10:100
pubmed: 19664258
Sports Med. 2004;34(4):269-80
pubmed: 15049718
Ann Rheum Dis. 1957 Dec;16(4):494-502
pubmed: 13498604
N Engl J Med. 2008 Nov 13;359(20):2135-42
pubmed: 19005197
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Br J Sports Med. 2015 Mar;49(5):335-42
pubmed: 23881894
J Bone Joint Surg Am. 2014 Aug 6;96(15):1233-1241
pubmed: 25100769
BMJ. 2018 Nov 5;363:k3750
pubmed: 30560792
Clin Orthop Relat Res. 1985 Sep;(198):43-9
pubmed: 4028566
BMJ. 2013 Jan 24;346:f232
pubmed: 23349407
BMJ. 2015 Jan 02;350:g7835
pubmed: 25555826
Osteoarthritis Cartilage. 2011 Apr;19(4):406-10
pubmed: 21255667
Br J Sports Med. 2009 May;43(5):347-51
pubmed: 18603576
Trials. 2015 May 09;16:210
pubmed: 25956385
PM R. 2010 Oct;2(10):935-44
pubmed: 20970763

Auteurs

Loretta Davies (L)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK. loretta.davies@ndorms.ox.ac.uk.

Jonathan Cook (J)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Jose Leal (J)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Department of Public Health, University of Oxford, Oxford, UK.

Carlos Morgado Areia (CM)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Beverly Shirkey (B)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

William Jackson (W)

Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Helen Campbell (H)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Department of Public Health, University of Oxford, Oxford, UK.

Heidi Fletcher (H)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Andrew Carr (A)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Karen Barker (K)

Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Sarah E Lamb (SE)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Paul Monk (P)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Sean O'Leary (S)

Royal Berkshire NHS Foundation Trust, Reading, UK.

Fares Haddad (F)

University College Hospital, London, UK.

Chris Wilson (C)

University Hospital of Wales, Cardiff, UK.

Andrew Price (A)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

David Beard (D)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Headington, Oxford, OX3 7LD, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH